Investor brief · ConfidentialThe picks-and-shovels of the
The picks-and-shovels of the
cell therapy decade.
Cell therapy TAM
$48B by 2030. 32% CAGR.
Global cell & gene therapy manufacturing is forecast to quadruple this decade. Bioreactor capacity is the rate-limiter.
Why now
Four converging shifts make this the bioreactor decade.
01
Approvals accelerating
Six new cell therapies approved in 2025; FDA designating CGT a strategic priority through 2030.
02
Manufacturing is the bottleneck
Industry-wide CAR-T capacity is 32% of forecast demand; commercial-scale single-use vessels are the constraint.
03
Allogeneic shift
Off-the-shelf platforms require commercial volumes the legacy stirred-tank ecosystem cannot deliver.
04
BioPure is the only linear platform
Identical mixing geometry across all five scales — protected by 84+ patents and trade secrets in vessel film chemistry.
IP moat
Defensible at every layer of the stack.
62
Granted patents
22
Pending applications
Proprietary
Vessel-film trade secrets
2042
Exclusivity through
Request data room access.
Detailed financials, manufacturing run-rate, and signed LOIs are available to qualified investors under NDA.
Request data room access →